AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06037460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 18FDG PET scan
Description: PETVAS calculation (to be performed between W0 and W8) (optional).
Study NCT05453500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01324986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic anti-reflux surgery
Study NCT05453500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT05453500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT05453500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT05453500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT05453500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV
Study NCT05453500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT05453500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05453500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT05453500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05453500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT05453500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample and cerebrospinal fluid collection
Study NCT06476392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 MG
Description: 2 Melatonin tablets (each 5 mg) once daily (egual 10 mg/day) in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 5 mg/day.
Study NCT06476392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets once daily in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 1 tablet.
Study NCT04608318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Cycles 1 - X: 420 mg daily, d1-28 p.o.
Study NCT04608318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Arm VG~Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o.~Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o.~Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o.~Arm VI~Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o.~Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o.
Study NCT04608318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.
Study NCT05012163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Letter, short message service (SMS) text, phone, and/or email
Study NCT05012163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Letter, SMS, phone, and/or email
Study NCT05012163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery
Description: Letter, SMS, phone, and/or email
Study NCT05253469 — intervention group
Intervention type: PROCEDURE
Intervention: Cryopreserved Aortic Homograft
Description: CAH is used for aortic root reconstruction and for repair of mitro-aortic curtain (emicommando procedure) and it is inserted as miniroot . In cases of PVE the infected prosthesis is removed with aggressive debridement of all infected and necrotic tissue. (7)The coronary ostia are prepared for reconstruction of aortic root. In complex valve endocarditis involving aortic and mitral valve a double homograft may be used.Mitro-aortic endocarditis intervalvular fibrosa is largely involved.The abscess cavity is precisely bounded and debrided. and a double homograft is used for the reconstruction (commando procedure
Study NCT05253469 — intervention group
Intervention type: PROCEDURE
Intervention: Stented/Non stented xenograft
Description: The insertion of stented/non stented xenograft may be performed using separate or continuos stich with or without teflon pledget. Biological valves may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic bioroot using bioprosthetic valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
Study NCT05253469 — intervention group
Intervention type: PROCEDURE
Intervention: Mechanical prostheses
Description: The insertion of conventional mechanical valves may be performed using separate or continuos stich with or without teflon pledget. Mechanical prostheses may be implated alone or combined with polyester or pericardial patch when reconstruction of annulus is required. In cases of aggressive lesions requiring root and /or intervalvular fibrosa reconstruction the choice of prosthetic valved conduit with a mechanical valve is considered acceptable alternatives to CAH although it should be guided by the surgeon's experience
Study NCT06199089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM313 Injection
Description: Intravenous CM313 administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to experimental group were treated with CD38 monoclonal antibody (CM313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment.
Study NCT06199089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Intravenous Placebo administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to placebo comparator group were treated with placebo of CM313 once a week for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of placebo of CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after placebo administration.
Study NCT05317234 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing
Description: The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
Study NCT05258162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Mobilisations are performed with minimum 6 seconds distraction stretch followed by partial release then followed by slow intermittent stretch at 3-4 seconds intervals.~  3 days per week for 3 weeks. Oscillations for 2 minutes at 2-3 oscillations per second.
Study NCT05258162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Hot pack for ten minutes.~Active and active-assisted exercises for the:~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation~* Lock and key exercises.~* Shoulder flexion, extension, abduction, adduction, and rotation (10 repetitions x 1sets) Low-intensity isometric resistance exercises for;~* Elbow flexion and extension~* Forearm supination and pronation (10 sec hold) (10 repetitions x 1 set) Resistance will be provided manually by the therapist. Along all these exercises Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.~  3 days per week for 3 weeks.
Study NCT06470321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexiquit Computerized Smoking Cessation Program
Description: Flexiquit is an avatar-led, self-directed computerized program delivering evidence-based techniques to assist with smoking cessation. It includes motivational interviewing, psychoeducation on nicotine addiction, cognitive-behavioral strategies for coping with cravings, relapse prevention, and stress/emotion regulation skills training. Participants receive the program over 6 months and their adherence is monitored. The program provides tailored feedback to support abstinence.
Study NCT05916768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelargonium sidoides extract EPs® 7630
Description: Kaloba® solution, a standardized alcoholic extract obtained from the roots of Pelargonium sidoides (EPs® 7630).
Study NCT05916768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: symptomatic treatments
Study NCT05046353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: Auditory remediation +/-D-serine
Study NCT05046353 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Auditory remediation +/-D-serine
Study NCT05176808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Achievements- Parent Coaching Intervention
Description: Children, along with a caregiver, will be randomized into one of two conditions to receive parent coaching guided by NDBI principles.
Study NCT04801550 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Millimeter waves local exposure
Description: several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure
Study NCT04801550 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Millimeter waves local exposure
Description: several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure
Study NCT04364958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A web based-Patient Decision Aid (PtDA) (shown on the computer)
Description: Patient decision aids (PtDAs) are tools that assist patients in making health decisions, when there is uncertainty about treatment choice, incorporating their personal preferences and values about the available treatment options. This PtDA will include information about GAD symptoms, diagnosis, causes, and benefits and risks associated to psychological and pharmacological treatments for GAD (based on the Clinical Practice Guidelines-GAD). It will also include a values clarification exercise, in which patients will have to rate the importance attributed to the different aspects of treatments (e.g., mode of administration, benefits, risks, time to improvement, probability of relapse).
Study NCT04364958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care.
Description: Patients in the control group will receive a fact sheet (one page) with general information on mental health as a part of usual care provided by the Canary Islands Health Service.
Study NCT06217666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCX-12
Description: treatment combining radiation therapy with PCX12
Study NCT06362681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Application of remineralizing agents on teeth and molars with MIH during 24 months of follow-up.
Study NCT05577234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention
Description: The dog accompanied by the zootherapist will participate in the care of sessions 1 and 2. During these two sessions, the dog will be present with the child in the waiting room until the end of the dental consultation. Session 3 will take place without the dog being present.The usual management with conventional behavioural strategies and possible administration of MEOPA will be implemented during the 3 treatment sessions.
Study NCT05577234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Venham scale modified by Veerkamp
Description: The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
Study NCT05577234 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Venham scale modified by Veerkamp
Description: The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
Study NCT04691804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzuloparib , Abiraterone acetate and Prednisone
Description: 1. Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po~3. Prednisone tablets (strength: 5 mg) 5mg, Bid po
Study NCT04691804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Description: 1. Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po~3. Prednisone tablets (strength: 5 mg)5mg, Bid po
Study NCT05364788 — intervention group
Intervention type: OTHER
Intervention: Retrospective tissue sample analysis
Description: Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
Study NCT06505447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daytime light exposure
Description: Participants will be exposed to a 10,000 lux light source within 3 feet of their face/eyes to promote the natural circadian rhythm for 2-3 hours from 10am to 12/1pm depending on their nap time at home
Study NCT06505447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daytime restricted feeding
Description: Participant's nutrition, parenteral or enteral, will be restricted to the hours when they are normally awake at home.
Study NCT06150339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OASIS Walking Intervention
Description: Communication Care Plan, Sit to Stand Activity, Walking Program
Study NCT05983809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technological rehabilitation
Description: Specific rehabilitation for balance disorder using the robotic platform
Study NCT05983809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological rehabilitation
Description: Specific rehabilitation for balance disorder using the robotic platform
Study NCT06313437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Menin inhibitor, 25 and 113 mg capsules, taken orally per protocol.
Study NCT06313437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Kinase inhibitor, capsule taken orally per protocol.
Study NCT06313437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
Study NCT06313437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
Study NCT05356910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPPEN
Description: OPPEN training sessions (three small-group and two one-on-one sessions) build skills for effective peer PrEP outreach through didactic instruction, group discussions, role-play exercises, and goal planning and problem-solving activities.
Study NCT05356910 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Condition
Description: Control sessions (three small-group and two one-on-one sessions) build skills for diet and nutrition behavior change through didactic instruction, group discussions, and goal planning and problem-solving activities.
Study NCT04874948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043
Description: Single oral administration of 14C-labeled radioactive 500mg BTZ-043
Study NCT06653322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR-1703
Description: HR-1703 will be administered by SC injection.
Study NCT06653322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered by the SC injection.
Study NCT06474221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Based Psychosocial Intervention (EBPSI)
Description: Electronic based Psycho-social Intervention (EBPSI) described as video based telepsychiatry sessions targeted on brief intervention and coping skills; with a total of 5 sessions on days 10, 30, 45, 60 and 90 after baseline intervention.
Study NCT06474221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Based Psychosocial Intervention (EBPSI)
Description: Electronic based Psycho-social Intervention (EBPSI) described as video based telepsychiatry sessions targeted on brief intervention and coping skills; with a total of 5 sessions on days 10, 30, 45, 60 and 90 after baseline intervention.
Study NCT05866419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThecaFlex DRx System
Description: The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
Study NCT06670300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardonilimab
Description: Subjects will receive cardonilimab 10mg/kg once every three weeks; The maximum duration of administration is 2 years until disease progression or death, toxicity becomes intolerable, subject voluntarily requests withdrawal, or investigator determines that subject needs to withdraw from the study.
Study NCT06682208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ES catheter
Description: ES catheter for postoperative pain control
Study NCT06682208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve cryoablation (INC)
Description: INC used for postoperative pain control
Study NCT06401447 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Simultaneously optimizing the target, dosage, and synchronized drugs for radiotherapy.
Study NCT06731959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flexlamose
Description: Fexlamose solution via nebulizer for 28 days
Study NCT06731959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution via nebulizer for 28 days
Study NCT06741722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF
Description: The specific administration times and dosages for the DCMG chemotherapy regimen are as follows:~M: Mitoxantrone Hydrochloride Liposome Injection: 15 mg/m², IV, on Day 1, every 4 weeks (q4w); D: Decitabine: 20 mg/m², IV, Days 1-5, q4w; (or Azacitidine: 75 mg/m², IV, Days 1-7, q4w); C: Cytarabine: 100 mg, IV, every 12 hours on Days 1-5, q4w; For patients with hypoplastic bone marrow, the dose of cytarabine injection is 10 mg, every 12 hours, q4w; G: G-CSF: 5 μg/kg, subcutaneous injection, from Day 0 until the white blood cell count exceeds 10.0×10\^9/L, at which point chemotherapy is stopped; or Pegylated Recombinant Human Granulocyte Stimulating Factor Injection: 100 μg/kg, subcutaneous injection, on Day 0.~One cycle lasts for 4 weeks, with a planned administration of 1 or 2 cycles.
Study NCT06741566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal saline group
Description: 3 ml of saline 0.9 % twice daily for 2 days preoperatively at fixed time ( 9 am and 6 pm)
Study NCT06741566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin
Description: 20 IU of regular insulin on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)